|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-16
|
|
pubmed:abstractText |
The isotype of epidermal growth factor receptor variant III (EGFRvIII) is often identified in glioblastomas. Previously, we created a mouse monoclonal antibody, 3C10 (IgG2b), that specifically recognized EGFRvIII, and a recombinant single-chain variable fragment of 3C10. The aim of the current study was to develop genetically engineered T cells, termed T-bodies, that express a chimeric receptor consisting of the 3C10 single-chain variable fragment coupled to signaling modules such as the CD3zeta (?) chain, for the treatment of tumors expressing mutant EGFR. After successful construction of the chimeric 3C10/CD3? T-cell receptor, its expression on the T-body was observed using western blotting and flow cytometry. The specificity of the T-body for EGFRvIII was evaluated using an interferon-gamma Elispot assay and a standard (51) Cr-release cytotoxicity assay. Furthermore, we demonstrated that the systemically delivered T-body infiltrated the intrabrain tumor and significantly delayed tumor growth. These results indicate that the T-body expressing the chimeric 3C10/CD3? T-cell receptor specifically recognized glioma cells expressing EGFRvIII. In conclusion, T-body-based immunotherapy appears to be a promising approach for the treatment of glioma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1349-7006
|
|
pubmed:author |
pubmed-author:Ichiro IwamiKenK,
pubmed-author:ItoDaikiD,
pubmed-author:ItoMotokazuM,
pubmed-author:IwamizuHidetakaH,
pubmed-author:MotomuraKazuyaK,
pubmed-author:NatsumeAtsushiA,
pubmed-author:NoritakeKanaK,
pubmed-author:OhnoMasasukeM,
pubmed-author:ToiYukiY,
pubmed-author:WakabayashiToshihikoT,
pubmed-author:YoshidaJunJ,
pubmed-author:YoshikawaKazuhiroK
|
|
pubmed:copyrightInfo |
© 2010 Japanese Cancer Association.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2518-24
|
|
pubmed:meshHeading |
pubmed-meshheading:20880333-Animals,
pubmed-meshheading:20880333-Antigens, Neoplasm,
pubmed-meshheading:20880333-Blotting, Western,
pubmed-meshheading:20880333-Brain Neoplasms,
pubmed-meshheading:20880333-Cell Line, Tumor,
pubmed-meshheading:20880333-Cell Separation,
pubmed-meshheading:20880333-Enzyme-Linked Immunospot Assay,
pubmed-meshheading:20880333-Female,
pubmed-meshheading:20880333-Flow Cytometry,
pubmed-meshheading:20880333-Genetic Engineering,
pubmed-meshheading:20880333-Glioma,
pubmed-meshheading:20880333-Humans,
pubmed-meshheading:20880333-Immunotherapy,
pubmed-meshheading:20880333-Mice,
pubmed-meshheading:20880333-Mice, SCID,
pubmed-meshheading:20880333-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20880333-Receptors, Antigen, T-Cell,
pubmed-meshheading:20880333-Retroviridae,
pubmed-meshheading:20880333-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20880333-Single-Chain Antibodies,
pubmed-meshheading:20880333-T-Lymphocytes,
pubmed-meshheading:20880333-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
|
|
pubmed:affiliation |
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya Center for Cell Therapy, Aichi Medical University, Nagakute, Aichi, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
